ReviewExpert opinion on biological therapy2009
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.
Review in Expert opinion on biological therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 58 citations in OpenAlex.
- Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.Pharmacology research & perspectives · 2023Trial
- Nipah virus: pathogenesis, genome, diagnosis, and treatment.Applied microbiology and biotechnology · 2025Review
- Mapping immunological and host receptor binding determinants of SARS-CoV spike protein utilizing the Qubevirus platform.The Journal of biological chemistry · 2023Article
- In silico designing of an epitope-based peptide vaccine cocktail against Nipah virus: an Indian population-based epidemiological study.Archives of microbiology · 2023Article
- Article
- Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.International immunopharmacology · 2022Review
- Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.Journal of Korean medical science · 2022Article
- Identification and Development of Therapeutics for COVID-19.mSystems · 2021Article
- Humoral immune mechanisms involved in protective and pathological immunity during COVID-19.Human immunology · 2021Review
- A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system.Journal of neurovirology · 2021Review
- Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections.Applied microbiology and biotechnology · 2021Review
- Article
- Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11.Science advances · 2021Article
- Immunobiology and immunotherapy of COVID-19: A clinically updated overview.Journal of cellular physiology · 2021Review
- Article
- Proteomic Approaches to Study SARS-CoV-2 Biology and COVID-19 Pathology.Journal of proteome research · 2021Article
- Immune-Based Therapy for COVID-19.Advances in experimental medicine and biology · 2021Article
- Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection.Frontiers in molecular biosciences · 2021Review
- Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay.ACS pharmacology & translational science · 2020Article
- Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments.International immunopharmacology · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundRecently, several potently neutralizing fully human monoclonal antibodies (hmAbs) targeting the severe acute respiratory syndrome-associated coronavirus (SARS CoV) S glycoprotein, and the G glycoprotein of the paramyxoviruses Hendra virus (HeV) and Nipah virus (NiV) have been discovered [corrected].
objectiveTo examine, compare and contrast the functional characteristics of hmAbs with the potential for prophylaxis and treatment of diseases caused by SARS CoV, HeV and NiV.
methodsA review of relevant literature. RESULTS/
conclusionsStructural, functional and biochemical analyses [corrected] have provided insights into the molecular mechanisms of receptor recognition and antibody neutralization, and suggested that these antibodies alone or in combination could fight the viruses' heterogeneity and mutability, which is a major problem in the development of effective therapeutic agents against viruses, including therapeutic antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.